McKesson (MCK) Financial History
Review McKesson annual and quarterly financial results, key ratios, insider transactions and SEC filing history in one chronological view. Data available from FY2008 through FY2026.
Financials
19 fiscal years, FY2008 to FY2026
Insider trades
512 trades
Risk factor changes
13 changes in the latest 10-K
Filings
Annual and quarterly reports
Compare
Side by side with another company
McKesson Financial Statements
History since FY2008. Annual, in US dollars. Source: 10-K XBRL data.
McKesson Revenue and Growth
Compare reported revenue and year-over-year revenue growth across available fiscal years.
McKesson Income Statements
Review revenue, gross profit, operating income, net income and earnings per share.
McKesson Balance Sheets
Review reported debt and book-value-based ratios where company data is available.
McKesson Cash Flow Statements
Compare reported free cash flow across the available fiscal history.
McKesson Financial Ratios
Compare net margin, price-to-earnings and price-to-book ratios by fiscal year.
| Fiscal year | FY2008 🔒 | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 🔒 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $264.0B | $276.7B | $309.0B | $359.1B | $403.4B |
| Revenue growth | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | — | +4.8% | +11.7% | +16.2% | +12.4% |
| Gross profit | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $13.1B | $12.4B | $12.8B | $13.3B | $14.6B |
| Operating income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $2.0B | $4.4B | $3.9B | $4.4B | $6.2B |
| Net income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $1.1B | $3.6B | $3.0B | $3.3B | $4.8B |
| Debt | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $6.1B | $5.8B | $5.8B | $5.8B | $6.7B |
| Free cash flow | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $4.0B | $4.8B | $3.9B | $5.5B | $5.7B |
| Net margin | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 0.4% | 1.3% | 1.0% | 0.9% | 1.2% |
| EPS (diluted) | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $7.23 | $25.03 | $22.39 | $25.72 | $38.38 |
| P/E ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 42.4× | 14.2× | 24.0× | 26.2× | 22.5× |
| P/B ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | — | — | — | — | — |
Daily closing prices, aggregated by calendar year.
| Year | 2000 🔒 | 2001 🔒 | 2002 🔒 | 2003 🔒 | 2004 🔒 | 2005 🔒 | 2006 🔒 | 2007 🔒 | 2008 🔒 | 2009 🔒 | 2010 🔒 | 2011 🔒 | 2012 🔒 | 2013 🔒 | 2014 🔒 | 2015 🔒 | 2016 🔒 | 2017 🔒 | 2018 🔒 | 2019 🔒 | 2020 🔒 | 2021 🔒 | 2022 | 2023 | 2024 | 2025 | 2026 (YTD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Open | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $247.66 | $374.85 | $461.19 | $571.33 | $818.81 |
| Close | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $375.11 | $463.19 | $569.79 | $819.99 | $1072.95 |
| High | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $401.62 | $476.28 | $634.98 | $895.45 | $1123.93 |
| Low | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $237.94 | $332.13 | $461.19 | $565.72 | $723.98 |
| Annual return | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | +50.9% | +23.5% | +23.0% | +43.9% | +30.8% |
McKesson Insider Transactions
From Form 4 filings. Showing the latest 5 of 512 trades.
| Traded | Filed | Insider | Type | Shares | Value | % of holdings |
|---|---|---|---|---|---|---|
| 2026-11-03 | 2026-11-05 | Francisco Fraga Executive VP, CIO and CTO | Option exercise | 398 | — | — |
| 2026-11-03 | 2026-11-05 | Francisco Fraga Executive VP, CIO and CTO | Tax withholding | 157 | $157K | — |
| 2026-11-04 | 2026-11-05 | Francisco Fraga Executive VP, CIO and CTO | Sold | 600 | $630K at ~$1,050 | 11% |
| 2026-11-03 | 2026-11-05 | Francisco Fraga Executive VP, CIO and CTO | Disposition to issuer | 398 | — | — |
| 2026-10-15 | 2026-10-19 | Francisco Fraga Executive VP, CIO and CTO | Sold | 800.491 | $797K at ~$996 | 13% |
McKesson Risk Factor Changes
Latest 10-K compared with the year before. 13 changes found.
Volatility and disruption in global capital and credit markets, including the bankruptcy or restructuring of certain financial institutions, reduced lending activity by financial institutions, reduced creditworthiness…
Changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for us and our customers and suppliers and might impair the financial soundness of our…
Inflationary conditions result in increased costs associated with our normal business operations and decreased levels of consumer commercial spending and, to the extent we are not able to offset such cost increases fr…
We are adversely impacted by changes in the economic environments in which we operate, including from inflation, an economic slowdown, a recession, or fluctuations in foreign currency exchange rates.
Our generic pharmaceuticals distribution business is subject to both product availability and pricing risks.
We are adversely impacted as a result of our distribution of generic pharmaceuticals.
sourcing and selling products due to a variety of causes that result in suppliers’ failure to satisfy production demand.
On March 10, 2020, the Company completed a separation of its interest in Change Healthcare LLC (“Change Healthcare JV”).
We might not realize the expected tax treatment from our split-off of Change Healthcare.
The Company intends to separate the Medical-Surgical Solutions segment into an independent company (“NewCo”).
Our planned separation of Medical-Surgical Solutions is contingent upon the satisfaction of certain conditions, may not be completed on the currently contemplated terms or timeline, or at all, and, if completed, may n…
When we decide to sell or otherwise divest assets or a business, we may encounter difficulty in finding buyers or exit strategies on acceptable terms or in a timely manner, which could delay the achievement of our str…
From time to time we are adversely impacted by delays or other difficulties with divestitures.
McKesson SEC Filings
Latest annual and quarterly reports, current reports, proxy statements and ownership filings.
| Form | Filed | Description | Document |
|---|---|---|---|
| Quarterly report (10-Q) | 2026-11-04 | Quarter ended Sep 30, 2026 | View document |
| Current report (8-K) | 2026-11-04 | Quarterly results | View document |
| Current report (8-K) | 2026-10-06 | Company update | View document |
| Current report (8-K) | 2026-08-28 | Company update | View document |
| Quarterly report (10-Q) | 2026-08-05 | Quarter ended Jun 30, 2026 | View document |
McKesson financial metrics by year
McKesson in the S&P 500 rankings
- #5 by revenue as of FY2026
- #91 by net income as of FY2026
- #70 by operating income as of FY2026
- #67 by free cash flow as of FY2026
- #9 by diluted earnings per share as of FY2026
S&P 500 is a trademark of S&P Dow Jones Indices LLC. StockYears is not affiliated with or endorsed by S&P Dow Jones Indices.
Compare McKesson with similar companies
- MCK vs CAH Cardinal Health
- MCK vs COR Cencora